Biomarkers and uses thereof for selecting immunotherapy intervention

US11397183B2 · kind B2 · utility

Assignees

• Fred Hutchinson Cancer Center · US
• University of Washington · US
• Bloodworks Northwest · US

Inventors

• W. Conrad Liles · Seattle, US
• Cameron J. Turtle · Seattle, US
• David MALONEY · Point of Rocks, US
• Stanley R. Riddell · Bothell, US
• Mark M. Wurfel · New York, US
• José A. López · Seattle, US
• Dominic W. Chung · Bellevue, US
• Junmei Chen · Seattle, US

Key dates

• Filing date: Feb 9, 2018
• Grant date: Jul 26, 2022
• Expiry date: Feb 9, 2038

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A90/10
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

The instant disclosure provides biomarkers and methods for identifying subjects at risk of developing cytokine release syndrome (CRS), neurotoxicity, or both after adoptive immunotherapy to guide preemptive intervention, modified therapy, or the like. For example, adverse event biomarkers may be measured in a subject before pre-conditioning chemotherapy, before immunotherapy (e.g., adoptive immunotherapy infusion comprising a chimeric antigen receptor (CAR) modified T cell), or shortly after pre-conditioning chemotherapy and/or immunotherapy. Exemplary biomarkers include temperature, cytokine levels and endothelial activation biomarkers, such as angiopoietin 2, von Willebrand factor (vWF), ratio of angiopoietin 2 to angiopoietin 1, and ratio of ADAMTS13 to vWF. Also provided are methods of treating subjects identified as at risk of developing cytokine release syndrome (CRS), neurotoxicity, or both to minimize such potential adverse events.